Stock Groups

Denmark’s Novo Nordisk to buy Dicerna Pharma for $3.3 billion -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – The facade of Chartres’ production facility in Chartres (north-central France), April 21 2016, shows the logo of Novo Nordisk, a multinational Danish pharmaceutical company. REUTERS/Guillaume Souvant

(Reuters] -Danish pharmaceutical maker Novo Nordisk (NYSE 🙂 will acquire Dicerna Pharmaceuticals Inc. for $3.3 Billion in cash, the U.S. drugs developer stated on Thursday.

A deal of $38.25 per Share represents an increase in value by 79.7% compared to Wednesday’s close price at Dicerna.

Since 2019, the two companies have collaborated in research to create multiple clinical candidates for various disorders, including type 2 diabetes (NASH), chronic liver disease and non-alcoholic Steatohepatitis(NASH), obesity, rare diseases, and type 2 diabetes.

Novo Nordisk plans to begin clinical development for the first investigational drug to be developed in this partnership by 2022.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]